Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 study of NT-0796 in healthy volunteers and patients with Parkinson's disease
NL-OMON59204Phase 1Completed
- Sponsor
- NodThera
- Start
- Apr 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1 trial of ruvonoflast in Parkinson's disease (PD) (2 arms), sponsored by NodThera. Primary endpoints: Incidence of treatment-emergent adverse events and Changes in clinical laboratory values. Started Apr 2023; status: completed.
02
Drugs
ruvonoflast
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NL-OMON59204.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59204.